These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 22561965)

  • 1. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.
    Noth I; Anstrom KJ; Calvert SB; de Andrade J; Flaherty KR; Glazer C; Kaner RJ; Olman MA;
    Am J Respir Crit Care Med; 2012 Jul; 186(1):88-95. PubMed ID: 22561965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.
    Kreuter M; Wijsenbeek MS; Vasakova M; Spagnolo P; Kolb M; Costabel U; Weycker D; Kirchgaessler KU; Maher TM
    Eur Respir J; 2016 Jun; 47(6):1776-84. PubMed ID: 27103382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
    Wilson AM; Clark AB; Cahn T; Chilvers ER; Fraser W; Hammond M; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett DR; Whyte M;
    JAMA; 2020 Dec; 324(22):2282-2291. PubMed ID: 33289822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.
    Kondoh Y; Azuma A; Inoue Y; Ogura T; Sakamoto S; Tsushima K; Johkoh T; Fujimoto K; Ichikado K; Matsuzawa Y; Saito T; Kishi K; Tomii K; Sakamoto N; Aoshima M; Araya J; Izumi S; Arita M; Abe M; Yamauchi H; Shindoh J; Suda T; Okamoto M; Ebina M; Yamada Y; Tohda Y; Kawamura T; Taguchi Y; Ishii H; Hashimoto N; Abe S; Taniguchi H; Tagawa J; Bessho K; Yamamori N; Homma S
    Am J Respir Crit Care Med; 2020 May; 201(9):1110-1119. PubMed ID: 31917621
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
    Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.
    Kreuter M; Bonella F; Maher TM; Costabel U; Spagnolo P; Weycker D; Kirchgaessler KU; Kolb M
    Thorax; 2017 Feb; 72(2):148-153. PubMed ID: 27708114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
    Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
    Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?
    Kubo H; Yanai M; Azuma A
    Am J Respir Crit Care Med; 2013 May; 187(9):1029-30. PubMed ID: 23634865
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
    Daniels CE; Lasky JA; Limper AH; Mieras K; Gabor E; Schroeder DR;
    Am J Respir Crit Care Med; 2010 Mar; 181(6):604-10. PubMed ID: 20007927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
    King TE; Albera C; Bradford WZ; Costabel U; du Bois RM; Leff JA; Nathan SD; Sahn SA; Valeyre D; Noble PW
    Am J Respir Crit Care Med; 2014 Apr; 189(7):825-31. PubMed ID: 24476390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
    Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
    BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
    Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
    Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
    Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.